Badger Meter, Inc.
BMI
$146.23
-1.45%
Badger Meter, Inc. is a leading provider of water management solutions, operating within the hardware, equipment, and parts segment of the technology sector. The company distinguishes itself as a market leader in flow measurement and control technologies, offering an integrated portfolio that includes hardware, connectivity, data visualization, and software for water utilities and industrial clients. The current investor narrative is dominated by a significant stock price decline following a major Q1 2026 earnings miss, which has raised concerns about near-term revenue weakness and margin contraction, despite management's long-term optimism tied to strategic acquisitions like UDlive.…
BMI
Badger Meter, Inc.
$146.23
Related headlines
Investment Opinion: Should I buy BMI Today?
Rating: Hold. The core thesis is that BMI is a high-quality company caught in a severe growth scare, making it a 'show me' story where investors should wait for evidence of a fundamental turnaround before committing new capital.
The Hold rating is supported by conflicting data points: the strong balance sheet (0 debt, 3.36 current ratio) and cash flow ($169.7M FCF) provide a floor, but the deteriorating fundamentals (Q4 revenue -7.6% YoY, margin compression) and still-rich valuation (forward PE 24.05x, PS 5.59) cap near-term upside. Analyst sentiment is mixed but leans bullish, suggesting the long-term narrative remains intact despite the near-term pain.
The thesis would upgrade to a Buy if revenue growth turns positive in the next quarter and gross margins stabilize above 42%, signaling the downturn was temporary. It would downgrade to a Sell if revenue decline accelerates beyond -10% or if the stock breaks decisively below the $112 support level on high volume. Relative to its own history and the growth expectations embedded in its multiples, the stock is currently fairly valued to slightly overvalued, pricing in a recovery that is not yet evident in the reported numbers.
Sign up to view all
BMI 12-Month Price Forecast
The outlook is clouded with high uncertainty. The company's operational quality is undeniable, but the near-term fundamentals are pointing in the wrong direction. The base case is a prolonged period of stagnation as the company works through its challenges. The stance would upgrade to bullish on confirmation of a revenue rebound and margin stabilization, likely requiring two consecutive quarters of improved data. It would turn bearish if the next earnings report shows further deterioration, validating the fear that the recent miss was not a one-off.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Badger Meter, Inc.'s 12-month outlook, with a consensus price target around $190.10 and implied upside of +30.0% versus the current price.
Average Target
$190.10
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$117 - $190
Analyst target range
Analyst coverage appears limited with only 3 analysts providing estimates, though institutional ratings data shows ongoing coverage from several major firms. The consensus sentiment from recent institutional actions is mixed but leans bullish, with firms like Stifel, RBC Capital, and Jefferies maintaining Buy or Outperform ratings, while Barclays holds an Underweight and Argus Research downgraded to Hold in February 2026 following the earnings disappointment. The target price range is not explicitly provided in the analyst data, but the wide dispersion in recent rating actions—from Buy to Underweight—signals high uncertainty and debate regarding the near-term outlook, with the low target likely pricing in continued execution risks and margin pressure, while the high target assumes the company's long-term strategy and acquisition synergies will successfully reignite growth.
Bulls vs Bears: BMI Investment Factors
The evidence currently tilts bearish, as the fundamental deterioration in revenue and margins is severe and recent. The bull case rests on a pristine balance sheet, strong cash flow, and an oversold technical setup, but these are defensive qualities. The single most important tension in the investment debate is whether the recent revenue decline is a temporary project timing issue (as management suggests) or the beginning of a sustained downturn in demand for its water solutions. The resolution of this tension, evidenced by the next quarter's revenue growth figure, will determine if the stock is a value trap or a compelling turnaround opportunity.
Bullish
- Fortress Balance Sheet with Zero Debt: The company has a pristine financial position with a debt-to-equity ratio of 0 and a robust current ratio of 3.36. This provides significant downside protection and ample liquidity to navigate near-term challenges without financial distress.
- Strong Profitability and Cash Generation: Despite recent pressure, the company remains solidly profitable with a Q4 2025 net margin of 15.25% and generated $169.7 million in TTM free cash flow. This strong cash flow underpins its operations and supports its 0.85% dividend yield.
- Deeply Oversold Technical Condition: The stock is down 51.03% over the past year and trades at just 5% of the distance from its 52-week low ($112.09) to its high ($256.08). This extreme oversold condition, coupled with a low beta of 0.68, suggests limited downside volatility and potential for a technical rebound.
- Analyst Consensus Leans Bullish: Despite recent downgrades, major firms like Stifel, RBC Capital, and Jefferies maintain Buy or Outperform ratings. This indicates institutional confidence in the company's long-term strategy, including the UDlive acquisition, to reignite growth.
Bearish
- Severe Revenue Deceleration and Miss: Q4 2025 revenue declined 7.6% year-over-year to $220.7 million, a sharp reversal from prior growth. This significant earnings miss triggered the stock's collapse to a 52-week low, raising fundamental concerns about demand and execution.
- Elevated Valuation Despite Collapse: The stock's trailing PE of 36.2x and forward PE of 24.05x remain elevated, especially for a company experiencing revenue contraction. The PS ratio of 5.59 and EV/EBITDA of 21.96 suggest the market still prices in a growth premium that may not be justified near-term.
- Sustained Margin Contraction: Gross margin compressed to 42.13% in Q4 2025 from higher levels earlier in the year, and net margin fell to 15.25%. This indicates cost inflation or an unfavorable sales mix is eroding profitability, compounding the top-line weakness.
- High Short Interest and Negative Momentum: A short ratio of 4.64 reflects significant bearish sentiment. The stock's 3-month performance of -24.68% and 1-month relative strength of -0.19% versus the SPY confirm persistent negative momentum, making any recovery fragile.
BMI Technical Analysis
The prevailing price trend is a severe and sustained downtrend, with the stock down 51.03% over the past year. The current price of $119.16 sits near the bottom of its 52-week range, trading at just 5% of the distance from the 52-week low of $112.09 to the high of $256.08, indicating the stock is deeply oversold and potentially at a value inflection point, though it remains a classic 'falling knife' scenario. Recent momentum shows a slight 3.13% gain over the past month, which diverges from the longer-term downtrend and could signal a tentative stabilization or dead-cat bounce; however, the 3-month performance remains deeply negative at -24.68%, and the stock's 1-month relative strength of -0.19% underperforms the SPY, suggesting any recovery is fragile. Key technical support is firmly established at the 52-week low of $112.09, while resistance lies far above near the 52-week high of $256.08; a breakdown below support would signal a continuation of the bear trend, while the stock's low beta of 0.679 indicates it has been significantly less volatile than the market during this decline, which may offer some downside protection but also suggests muted momentum on any potential rebound.
Beta
0.68
0.68x market volatility
Max Drawdown
-55.4%
Largest decline past year
52-Week Range
$112-$250
Price range past year
Annual Return
-39.2%
Cumulative gain past year
| Period | BMI Return | S&P 500 |
|---|---|---|
| 1m | +19.3% | -1.7% |
| 3m | -6.7% | +13.7% |
| 6m | -17.1% | +9.2% |
| 1y | -39.2% | +20.7% |
| ytd | -17.1% | +9.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMI Fundamental Analysis
Revenue growth has decelerated and turned negative in the most recent quarter, with Q4 2025 revenue of $220.7 million representing a 7.6% year-over-year decline from the prior-year quarter; the sequential trend from Q1 to Q4 2025 shows revenue peaked in Q2 at $238.1 million and has since softened, indicating potential demand headwinds or project timing issues. The company remains profitable with a net income of $33.6 million in Q4 2025, but margins are under pressure, as the gross margin of 42.13% and net margin of 15.25% for that quarter have compressed from higher levels seen earlier in the year, suggesting cost inflation or unfavorable sales mix are impacting profitability. The balance sheet is exceptionally strong with zero debt (debt-to-equity of 0) and robust liquidity evidenced by a current ratio of 3.36; the company generates substantial cash flow, with free cash flow over the trailing twelve months of $169.7 million and an ROE of 19.86%, indicating it can fund operations and growth internally without financial strain.
Quarterly Revenue
$220706000.0B
2025-12
Revenue YoY Growth
+7.57%
YoY Comparison
Gross Margin
42.13%
Latest Quarter
Free Cash Flow
$169672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMI Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 36.2x, while the forward PE is significantly lower at 24.05x, indicating the market expects a substantial recovery in earnings over the next year, likely pricing in a rebound from the recent earnings miss. Compared to sector averages, the stock's valuation is difficult to contextualize precisely without explicit industry multiples in the data, but its high single-digit PS ratio of 5.59 and EV/EBITDA of 21.96 suggest a premium pricing relative to many industrial hardware peers, which may only be justified if the company can return to its historical growth and margin profile. Historically, the current trailing PE of 36.2x is below the stock's own recent historical highs seen in mid-2025 (e.g., 52.05x in Q2 2025) but above its longer-term average, placing it in a mid-to-upper range of its own historical band and suggesting the market has not fully priced out previous growth optimism despite the recent sharp correction.
PE
36.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 35x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's ability to reverse its recent negative revenue trajectory and margin compression. Q4 2025 revenue declined 7.6% YoY, and gross margins have softened from earlier peaks. While the balance sheet is strong, the elevated valuation (forward PE of 24.05x) is predicated on a significant earnings recovery; failure to achieve this would lead to multiple compression. The company's dependence on the U.S. market (the vast majority of revenue) also presents concentration risk if municipal water utility spending slows.
Market & Competitive Risks include the stock's high valuation premium despite its recent crash. Trading at a PS of 5.59 and EV/EBITDA of 21.96, it likely commands a premium to many industrial hardware peers. If growth does not reaccelerate, these multiples are vulnerable to severe compression. The low beta of 0.679, while offering downside protection, also suggests the stock may not participate fully in a broad market rally, leading to continued underperformance. Recent news highlights the bearish technical setup and investor skepticism following the Q1 2026 earnings miss.
The Worst-Case Scenario involves a continuation of the revenue decline and margin pressure into subsequent quarters, leading to further analyst downgrades and a loss of the 'growth' premium. This could trigger a sell-off pushing the stock through its key technical support at the 52-week low of $112.09. Given the stock's 52-week high of $256.08 and current price of $119.16, a realistic downside in an adverse scenario could see a retest of the $100 level, representing a potential loss of approximately -16% from the current price, extending the maximum drawdown beyond the current -55.38%.
FAQ
The primary risk is sustained fundamental deterioration, specifically continued revenue decline and margin compression, as seen in Q4 2025. Second is valuation compression risk; if growth does not return, the current premium multiples (e.g., forward PE 24x) could contract sharply. Third is sentiment and technical risk, evidenced by high short interest (short ratio 4.64) and the stock trading just 5% above its 52-week low, making it vulnerable to further selling on bad news. A secondary risk is its dependence on U.S. municipal water spending, which could be delayed in an economic slowdown.
The 12-month forecast is highly bifurcated, with three primary scenarios. The base case (55% probability) sees the stock trading between $130 and $160 as growth stabilizes at low levels. The bull case (25% probability) projects a rally to $180-$220 on a successful growth rebound. The bear case (20% probability) warns of a drop to $100-$115 if the downturn deepens. The most likely outcome is the base case, predicated on the assumption that the company's strong operational foundation prevents a complete collapse but that regaining its prior growth trajectory will take time.
BMI's valuation is complex and sits in a gray area. Its trailing PE of 36.2x is elevated, but the forward PE of 24.05x reflects market expectations for an earnings rebound. Compared to likely industrial peers, metrics like its PS ratio of 5.59 and EV/EBITDA of 21.96 suggest a premium pricing. Relative to its own history, the stock is below its 2025 highs but not at bargain-basement levels. The valuation implies the market is still paying for future growth, making the stock fairly valued to slightly overvalued until that growth materializes. It is not deeply undervalued based on current fundamentals.
BMI is a high-risk, high-potential-reward stock at its current deeply oversold level, but it is not a clear-cut 'good buy' for all investors. For aggressive investors seeking a turnaround play, the strong balance sheet (0 debt) and cash flow provide a margin of safety. However, with revenue growth recently turning negative (-7.6% YoY) and valuation still not cheap (forward PE 24x), it is a 'show me' story. It could be a good buy for patient investors who believe the downturn is temporary, but others should wait for concrete evidence of a fundamental recovery in the next quarterly report.
BMI is unsuitable for short-term trading due to its low beta (0.68) and negative momentum, which limit near-term upside catalysts. It is best considered a long-term investment (minimum 2-3 year horizon) for investors betting on a fundamental turnaround. The company's strong balance sheet, cash-generative business, and leading market position support a long-term hold thesis. However, given the current uncertainty, investors must be prepared for volatility and have the patience to wait for the company's strategic initiatives, like the UDlive integration, to bear fruit and reignite growth.